Skip main navigation

£199.99 £139.99 for one year of Unlimited learning. Offer ends on 28 February 2023 at 23:59 (UTC). T&Cs apply

Find out more

Relief of symptoms

Aims of management of COPD.
Bronchodilators: Inhaled bronchodilators are central to symptom management in COPD and are the most common inhalers prescribed to reduce symptoms.

Based on the severity assessment of COPD, there are two types of bronchodilators: beta2-agonists and antimuscarinics. They both work in COPD and can be combined. Beta2-agnosist tend to be cheaper than antimuscarinics in most healthcare systems:

  1. Regular and as-needed use of short-acting beta2-agonist (SABA) or Short-acting antimuscarinic antagonist (SAMA)

  2. If symptoms persist, prescribe regular LABAs (Long-acting beta2-agonists) or LAMAs (Long-acting antimuscarinic antagonists)

  3. Combination treatment with a LABA and LAMA increases FEV1 and reduces symptoms compared to monotherapy.

The article below from NICE looks at the non-pharmacological management and use of inhaled therapies.

This article is from the free online

Chronic Respiratory Diseases (CRD) in Primary Care Settings

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education